Vext Science Inc
CNSX:VEXT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its 3-Year Average (5.9), the stock would be worth CA$0.54 (90% upside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 3.1 | CA$0.29 |
0%
|
| 3-Year Average | 5.9 | CA$0.54 |
+90%
|
| 5-Year Average | 6.7 | CA$0.61 |
+116%
|
| Industry Average | 10.4 | CA$0.96 |
+236%
|
| Country Average | 10.9 | CA$1.01 |
+255%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
V
|
Vext Science Inc
CNSX:VEXT
|
53m CAD | 3.1 | -2.3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
867B USD | 51.6 | 42 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
555.4B USD | 22.6 | 26.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 13.2 | 19.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
224.8B GBP | 20.4 | 29.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.8B CHF | 14.6 | 20 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
283.6B USD | 17.2 | 15.5 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 907.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 9.2 | 10.7 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.6B USD | 13 | 19.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.8B USD | 8.4 | 16.8 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 7.2 |
| Median | 10.9 |
| 70th Percentile | 17 |
| Max | 26 053.9 |
Other Multiples
Vext Science Inc
Glance View
Vext Science, Inc. engages in the cultivation, extraction, and wholesale distribution of cannabis products. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2019-05-13. The firm utilizes a vertical integration business model to execute all aspects of cultivation, extraction, manufacturing (tetrahydrocannabinol (THC) and cannabidiol (CBD) cartridges, concentrates, edibles), retail dispensary, and wholesale distribution of cannabis THC and hemp CBD products. The company provides these management and marketing services in Arizona to two licensed dispensaries. The firm has developed a standard operating procedures (SOPs) to produce a full line of branded flower, Vapen branded THC and CBD distillates, concentrates, extracts, and edibles. The company operates a service business for cannabis cultivation and processing located in the State of Arizona. The firm's products produced under contract are sold through Herbal Wellness Center and Organica Patient Group Medical Marijuana Dispensary, both licensed not-for-profit dispensaries located in Phoenix, Arizona.
